CLINICAL TRIALS PROFILE FOR MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE
✉ Email this page to a colleague
All Clinical Trials for MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00415597 ↗ | Study of Embeda (Kadian NT, ALO-01) in Subjects With Chronic Moderate to Severe Nonmalignant Pain | Completed | Pfizer | Phase 3 | 2006-12-01 | Open-Label, Safety Study to evaluate the long-term safety of Kadian NT (ALO-01) administered for up to 12 months. |
NCT00420992 ↗ | A Study of Embeda (Kadian NT, ALO-01) in Subjects With Pain Due to Osteoarthritis of the Hip or Knee | Completed | Pfizer | Phase 3 | 2006-12-01 | The purpose of this study is to evaluate the efficacy of Kadian NT (ALO-01) compared with placebo for treating moderate to severe chronic pain over a 12 week period. |
NCT01179191 ↗ | Conversion to Embeda With Rescue Trial | Terminated | Pfizer | Phase 4 | 2010-08-01 | The purpose of the research study is to find out if opioid dependent chronic pain patients who are judged by their physician to be eligible to change their current opioid medicine and to participate in this study can be successfully adjusted to a stable dose of EMBEDA (morphine sulfate and naltrexone hydrochloride). The study will also assess each patient's risk for prescription opioid abuse, misuse and diversion. |
NCT01665209 ↗ | Bioequivalence Study of Morphine Sulfate 60 mg Extended-Release Tablets Under Fed Conditions | Completed | Ranbaxy Inc. | Phase 1 | 2006-10-01 | The study was to evaluate the relative bioavailability of morphine and morphine-6-glucuronide from 2 tablet products and determine if the 2 products were bioequivalent to each other. |
NCT01665222 ↗ | Bioequivalence Study of Morphine Sulfate 60 mg Extended-Release Tablets Under Fasting Conditions | Completed | Ranbaxy Inc. | Phase 1 | 2006-10-01 | The study was to evaluate the relative bioavailability of morphine and morphine-6-glucuronide from 2 tablet products and determine if the 2 products were bioequivalent to each other. |
NCT02101554 ↗ | Safety and Pharmacokinetic Study of EMBEDA in Children Ages 7-17 With Pain | Terminated | Pfizer | Phase 4 | 2015-04-24 | Safety and pharmacokinetics of an abuse-deterrent, extended-release formulation of morphine sulfate with a sequestered naltrexone core in children 7-17 with moderate-severe pain. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE
Condition Name
Clinical Trial Locations for MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE
Trials by Country
Clinical Trial Progress for MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE
Clinical Trial Phase
Clinical Trial Sponsors for MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE
Sponsor Name